<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01503567</url>
  </required_header>
  <id_info>
    <org_study_id>HAEM-3971</org_study_id>
    <secondary_id>U1111-1124-6665</secondary_id>
    <nct_id>NCT01503567</nct_id>
  </id_info>
  <brief_title>Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries</brief_title>
  <acronym>HAEMOcare</acronym>
  <official_title>Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted in Africa and Asia. The aim of this study is to evaluate in the
      participating countries the orthopaedic status and the degree of arthropathy of severe
      haemophilia patients in general.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Type of haemophilia and inhibitor characteristics: Against FVIII or FIX; high or low titre; anamnestic response (high or low responder)</measure>
    <time_frame>After 6 months (recruitment and data collection)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical (using Haemophilia joint score) and radiological (using Pettersson score) orthopaedic status of defined joints: Elbow, knees and ankles in relation to haemophilia A or B</measure>
    <time_frame>After 6 months (recruitment and data collection)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean orthopaedic score in the 4 groups according to the Pettersson and Haemophilia joint scores</measure>
    <time_frame>After 6 months (recruitment and data collection)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usage of anti haemophilic treatment in IU/kg</measure>
    <time_frame>During the last year preceding patient recruitment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - EQ-5D (Euro Quality - 5 Domains) questionnaire</measure>
    <time_frame>After 6 months (recruitment and data collection)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Economic aspects of the management of haemophiliacs and its burden on patient/family and community resources</measure>
    <time_frame>After 6 months (recruitment and data collection)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Living characteristics of the patient's household</measure>
    <time_frame>After 6 months (recruitment and data collection)</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">282</enrollment>
  <condition>Congenital Bleeding Disorder</condition>
  <condition>Haemophilia A</condition>
  <condition>Haemophilia A With Inhibitors</condition>
  <condition>Haemophilia B</condition>
  <condition>Haemophilia B With Inhibitors</condition>
  <arm_group>
    <arm_group_label>Subjects 6 to 18 years old without inhibitors</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects 6 to 18 years old with inhibitors</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects above18 years old without inhibitors</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects above 18 years old with inhibitors</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No treatment given</intervention_name>
    <description>Subject will only fill out a questionaire</description>
    <arm_group_label>Subjects 6 to 18 years old without inhibitors</arm_group_label>
    <arm_group_label>Subjects 6 to 18 years old with inhibitors</arm_group_label>
    <arm_group_label>Subjects above18 years old without inhibitors</arm_group_label>
    <arm_group_label>Subjects above 18 years old with inhibitors</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Male patients at least 6 years old with severe congenital haemophilia A or B (FVIII or FIX
        activities below 1% or level below 1U dL^-1) without inhibitor or with inhibitors against
        FVIII or FIX
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient (and/or parents or the patient's legally acceptable representative, if
             applicable) must give signed and dated informed consent before enrolment in the study

          -  Male patients at least 6 years old with diagnosis of severe congenital haemophilia A
             or B with or without inhibitors

          -  Patients receiving on demand replacement factors/bypassing agents therapy

        Exclusion Criteria:

          -  Clinically relevant coagulation disorders other than congenital haemophilia A or B

          -  Patients on currently active treatment for HCV (Hepatitis C Virus) or HIV (Human
             Immune Deficiency Virus) infections
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <zip>560001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Casablanca</city>
        <zip>20000</zip>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Muscat</city>
        <country>Oman</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sandton</city>
        <zip>2146</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>Morocco</country>
    <country>Oman</country>
    <country>South Africa</country>
  </location_countries>
  <removed_countries>
    <country>Algeria</country>
  </removed_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Gupta N, Belhani M, Benbouzid A, Andaloussi M El, Maani K, Mahlangu J, Wali Y, Saad HA, Fegoun SB el. The Haemocare Protocol - A composite method to measure the disease burden from Haemophilia in developing countries. European Hematology Association 2013; Country: Sweden City: Stockholm</citation>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2012</study_first_submitted>
  <study_first_submitted_qc>January 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2012</study_first_posted>
  <last_update_submitted>January 17, 2017</last_update_submitted>
  <last_update_submitted_qc>January 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

